Acta Scientific Biotechnology

Review Article Volume 3 Issue 3

Covid-19 Vaccines: Overview, Comparative Analysis and Dynamics

Doaa Zamel1,2,4* and Atta Ullah Khan3,4

1Department of Biochemistry, Faculty of Science, Helwan University, Helwan, Egypt
2Department of Environmental Engineering, Institute of Urban Environment, CAS, China
3CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, China
4University of Chinese Academy of Sciences, Beijing, PR China

*Corresponding Author: Doaa Zamel, Department of Biochemistry, Faculty of Science, Helwan University, Helwan, Egypt.

Received: May 05, 2022; Published: June 21, 2022

Abstract

As the mankind experienced the serious situation of COVID-19 that hit the whole world, scientists thought that vaccines are the nearest solution to eliminate this pandemic and minimizes its severity. Therefore, they started the race to develop an effective and safe vaccine, each group in their laboratory working day and night to save the whole world. Vaccines proved their protection roles against many past infections, and here against COVID-19, extensive studied and new technologies were accurately tested. The results came up with several vaccines ready to use and others still under clinical trials, however, fear form vaccines and questions on the best and more safe vaccine are everywhere among people. To be clear, gaining trust in the market became not easy for vaccine production companies, especially in this strong competition after the availability of several vaccine at the same time. By time passage, vaccine distribution and intake will be easier, particularly when people could trust these vaccines and be sure of their safety and efficacy. Many countries could produce vaccines, among of them; China, United States, United Kingdom and Russia and their vaccines spread internationally nowadays. To convince people which vaccine is the best and most safe, it is not easy and this matter will come after long-term of use and experience. However, there is no guarantee that these vaccines will provide 100% protection against COVID-19 and this will be proved also after long-term of use. This review presents comparative analysis of the most common types of COVID-19 vaccines which are already in use in the world market and the dynamics of vaccination over all the world.

Keywords: COVID-19; Vaccines; Types; Efficacy; Safety; Analysis; Dynamics

References

  1. El Zowalaty ME and JD Järhult. “From SARS to COVID-19: A previously unknown SARS-related coronavirus (SARS-CoV-2) of pandemic potential infecting humans–Call for a One Health approach”. One Health 9 (2020): 100124.
  2. Waris A., et al. “COVID-19 outbreak: current scenario of Pakistan”. New Microbes and New Infections (2020): 100681.
  3. Abd El-Aziz TM and JD Stockand. “Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)-an update on the status”. Infection, Genetics and Evolution (2020): 104327.
  4. da Silva SJR., et al. “Clinical and laboratory diagnosis of SARS-CoV-2, the virus causing COVID-19”. ACS Infectious Diseases9 (2020): 2319-2336.
  5. Boni MF., et al. “Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic”. Nature Microbiology11 (2020): 1408-1417.
  6. Helmy YA., et al. “The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control”. Journal of Clinical Medicine4 (2020): 1225.
  7. Zhou F., et al. “Economic evaluation of the routine childhood immunization program in the United States, 2009”. Pediatrics 4 (2014): 577-585.
  8. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. “The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2”. Nature Microbiology4 (2020): 536.
  9. Plotkin SA. “Vaccines, vaccination, and vaccinology”. The Journal of Infectious Diseases9 (2003): 1349-1359.
  10. Hotez PJ., et al. “COVID-19 vaccines: neutralizing antibodies and the alum advantage”. Nature Reviews Immunology7 (2020): 399-400.
  11. Kashte S., et al. “COVID-19 vaccines: rapid development, implications, challenges and future prospects”. Human Cell (2021): 1-23.
  12. Stafford IA., et al. “The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations”. American Journal of Obstetrics and Gynecology5 (2021): 484-495.
  13. Calina D., et al. “Towards effective COVID‑19 vaccines: Updates, perspectives and challenges”. International Journal of Molecular Medicine1 (2020): 3-16.
  14. Forni G and A Mantovani. “COVID-19 vaccines: where we stand and challenges ahead”. Cell Death and Differentiation2 (2021): 626-639.
  15. Pollard AJ and EM Bijker. “Publisher Correction: A guide to vaccinology: from basic principles to new developments”. Nature Reviews Immunology (2021): 1-1.
  16. Uddin M., et al. “SARS-CoV-2/COVID-19: viral genomics, epidemiology, vaccines, and therapeutic interventions”. Viruses5 (2020): 526.
  17. Polack FP., et al. “Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine”. New England Journal of Medicine27 (2020): 2603-2615.
  18. Knoll MD and C Wonodi. “Oxford–AstraZeneca COVID-19 vaccine efficacy”. The Lancet10269 (2021): 72-74.
  19. Pollard AJ and EM Bijker. “A guide to vaccinology: from basic principles to new developments”. Nature Reviews Immunology (2020): 1-18.
  20. Alteri A., et al. “Cryopreservation in reproductive medicine during the COVID-19 pandemic: rethinking policies and European safety regulations”. Human Reproduction12 (2020): 2650-2657.
  21. Zhao X., et al. “Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening”. European Journal of Clinical Microbiology and Infectious Diseases7 (2020): 1209-1220.
  22. Speiser DE and MF Bachmann. “COVID-19: Mechanisms of vaccination and immunity”. Vaccines 3 (2020): 404.
  23. Calina D., et al. “Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development”. Immunologic Research (2020): 1-10.
  24. Koven S and Engla. Journal-2010-New England journal (2020).
  25. Palacios R., et al. “Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac–PROFISCOV: A structured summary of a study protocol for a randomised controlled trial”. Trials 1 (2020): 1-3.
  26. Callaway E and S Mallapaty. “Novavax covid vaccine protects people against variants”. Nature (2021): 590-517.
  27. Jones I., et al. “COVID-19 vaccine candidate appears safe and effective”. The Lancet10275 (2021): 642-643.
  28. Palareti G., et al. “Comparison between different D‐Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study”. International Journal of Laboratory Hematology1 (2016): 42-49.
  29. Cortes-Perez NG., et al. “Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria”. Vaccine 36 (2007): 6581-6588.
  30. Williams JA., et al. “Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production”. Biotechnology Advances4 (2009): 353-370.
  31. Rohn J. Inovio. Nature Publishing Group (2013).
  32. Mahase E. “Covid-19: Vaccine candidate may be more than 90% effective, interim results indicate”. 2020, British Medical Journal Publishing Group (2020).
  33. Organization WH. Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZeneca: background document to the WHO Interim recommendations for use of the AZD1222 (ChAdOx1-S [recombinant]) vaccine against COVID19 developed by Oxford University and AstraZeneca, 1 March 2021. 2021, World Health Organization (2021).
  34. Tobaiqy M., et al. “Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine reported to Eudra Vigilance database”. Vaccines 4 (2021): 393.
  35. Food U and D Administration. “Vaccines and related biological products advisory committee meeting December 10, 2020”. Pfizer-BioNTech COVID-19 vaccine. Silver Spring, MD: US Food and Drug Administration (2020).
  36. Noor R. “Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines”. Current Clinical Microbiology Reports (2021): 1-8.
  37. Zhu FC., et al. “Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial”. The Lancet10240 (2020): 1845-1854.
  38. AboulFotouh K., et al. “Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration”. AAPS PharmSciTech3 (2021): 1-15.
  39. Wu Z., et al. “Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial”. The Lancet Infectious Diseases (2021).
  40. Expanded Program on Immunization, P.N.H.C., Islamabad, Guidelines and Standard Operating Procedures (SOPs) Sinovac Vaccine (CoronaVac). Date: 21 April 2021 Document Code: 63-01 Version: 01 (2021).
  41. “Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial”. Jan 28, 2021 at 4:05 PM EST (2021).
  42. HSA/ HPSIU/ NIH, P.N.H.C., Islamabad. COVID-19 Vaccination Updated Sputnik V Vaccine Guidelines. (2021).
  43. Baraniuk C. “Covid-19: What do we know about Sputnik V and other Russian vaccines?” BMJ (2021): 372.
  44. Lawton G. “Sputnik V vaccine goes global”. Elsevier (2021).
  45. Li Q and H Lu. “Latest updates on COVID-19 vaccines”. BioScience Trends (2021).
  46. Yan ZP., et al. “COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials”. Pharmaceuticals 5 (2021): 406.
  47. Mahase E. “Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant”. British Medical Journal Publishing Group (2021).
  48. Mahase E. “Covid-19: South Africa pauses use of Oxford vaccine after study casts doubt on efficacy against variant”. British Medical Journal Publishing Group (2021).
  49. data, o.w.i. Statistics and Research Coronavirus (COVID-19) Vaccinations (2021).

Citation

Citation: Doaa Zamel and Atta Ullah Khan. “Covid-19 Vaccines: Overview, Comparative Analysis and Dynamics".Acta Scientific Biotechnology 3.3 (2022): 24-33.

Copyright

Copyright: © 2022 Doaa Zamel and Atta Ullah Khan. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate33%
Acceptance to publication20-30 days

Indexed In



News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 20, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US